Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Abstract
Objective To describe successful long-term tumor control in metastatic adrenocortical carcinoma, a relatively rare tumor with limited treatment options outside of surgery. Methods We present the clinical, radiologic, and pathologic findings in a patient with failure of or intolerance to conventional treatments for metastatic adrenocortical carcinoma. Results A 48-year-old man with adrenocortical carcinoma had disease progression with systemic therapies including mitotane, 5-fluorouracil, streptozotocin, bevacizumab, and external beam radiation therapy. Treatment with all chemotherapeutic drugs was ceased, and he was prescribed mebendazole, 100 mg twice daily, as a single agent. His metastases initially regressed and subsequently remained stable. While receiving mebendazole as a sole treatment for 19 months, his disease remained stable. He did not experience any clinically significant adverse effects, and his quality of life was satisfactory. His disease subsequently progressed after 24 months of mebendazole monotherapy. Conclusion Mebendazole may achieve long-term disease control of metastatic adrenocortical carcinoma. It is well tolerated and the associated adverse effects are minor.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent anecdotal evidence from two case reports supports the possibility of mebendazole being repurposed as an anticancer drug by documenting its success in managing metastatic patients.
“Recent anecdotal evidence from two case reports has further supported the possibility of MBZ being repurposed as an anticancer drug by documenting its success in managing metastatic patients.164,165”
From Drug repurposing for cancer therapy (2024) · cites this paper as [164]
Many clinical trials with mebendazole are currently on-going; however, published documents in treatment of cancer patients have so far been limited only to 2 case reports.
“Many clinical trials with mebendazole are currently on-going [35]; however, published documents in treatment of cancer patients have so far been limited only to 2 case reports [370,371] (Table 6).”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [370]
A combined use of mebendazole with other cytotoxic drugs was suggested to have synergistic effects.
“A combined use of mebendazole with other cytotoxic drugs was suggested to have synergistic effects [370].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [370]
In the first case report, a 48-year-old man with adrenocortical carcinoma with liver metastasis, after conventional treatments failed and were intolerable, mebendazole (200 mg daily for 19 months) brought about regression of hepatic metastatic lesions with subsequent stability for 19 months, although the disease progressed after 24 months; the patient had no clinically adverse effects, and the质量of
“Mebendazole (200 mg daily for 19 months) brought about regression of hepatic metastatic lesions with subsequent stability for 19 months, although the disease progressed after 24 months; however, the patient had no clinically adverse effects, and the quality of life was satisfactory [370].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [370]
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · see citing works
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443 · see citing works
“164,165 Together, these fi ndings demonstrate the critical need to learn more about the therapeutic pro fi le of MBZ to ensure its safety in oncological applications and determine its ef fi cacy as a groundbreaking anticancer treatment.”
BackgroundDrug repositioning: a machine-learning approach through data integration
Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, R., Kere, J., D’Amato, M., & Greco, D. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-30 · Cited by 349 · see citing works
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329 · see citing works
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286 · see citing works
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55 · see citing works
- Authors
- Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Worden, Francis P.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 17
- Issue
- 3
- Pages
- e59-e62
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2059980115
- Cited by
- 53
- References
- 2
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 5 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 2 · 2014: 1 · 2013: 3
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Keywords
- mebendazole, adrenocortical carcinoma, metastatic adrenocortical carcinoma, monotherapy, long-term disease control, refractory cancer, stable disease, adverse effects, quality of life
- MeSH terms
- Adrenal Cortex Neoplasms, Antineoplastic Agents, Humans, Male, Mebendazole, Middle Aged, Neoplasm Metastasis, Radiography, Recurrence, Treatment Outcome, Adrenocortical Carcinoma, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
